Since the advent of advanced genomics, and the subsequent rise of automation, the data generated in clinical testing and research sees a 100 fold increase each year making the storage, security and management of patient data quite a daunting task for companies to mine the data to find the factors that drive a patient’s disease. That’s where BioDiscovery comes in. Their flagship solution NxClinical, is a unique software tool for integrated analysis of copy number, sequence variants, and allelic changes obtained from multiple technologies. The solution combines NGS and Array data through advanced mining and filtering techniques which allows the data to be clear and digestible for clinicians.
BioDiscovery launches the NxClinical Center of Excellence initiative with Victorian Clinical Genetics Services as its first partner
PerkinElmer Genomics has selected BioDiscovery's NxClinical software as its choice for genomic data analysis for its services.
Nexus Copy Number 10.0 is a highly robust, intuitive, and multi-platform software for both copy number calling and downstream statistical analyses. A key feature of Nexus Copy Number is its ability to derive high quality copy number calls from many flavors of NGS (whole exome, whole genome, shallow, targeted panel, and normal depth of coverage sequencing).
NxClinical 4.1 is a unique software solution for integration of copy number, sequence variants, and allelic changes obtained from microarray and NGS technologies. NxClinical 4.1 allows combined analysis and interpretation of all genomic variants on a single, platform agnostic system.
BioDiscovery announced today an agreement with Be Creative Lab in Beijing, China to be the exclusive reseller and distributor of BioDiscovery products in China.
BioDiscovery launches NxClinical 4.0, a unique system allowing analysis and interpretation of CNV, SNV, and AOH from a single NGS assay.
The new features in Nexus Copy Number 9.0 really enhance the usability of WES, WGS, targeted panels and low-pass sequencing for copy number analysis.
GENALICE and BioDiscovery announce a co-marketing partnership to offer their products together as a turn-key end-to-end solution for the use of next-generation sequencing (NGS) data to interpret genomes.